INVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023

Rhea-AI Summary

INVO Bioscience (NASDAQ: INVO) is set to announce its financial results for Q4 and fiscal year 2022, ending December 31, 2022, after market close on April 17, 2023. Following the release, a conference call will be held at 4:30 pm ET to discuss these results. The company specializes in the fertility sector, focusing on expanding access to its INVOcell medical device and the intravaginal culture procedure, aimed at providing affordable fertility treatments. INVO has operational centers in North America and plans to continue its commercialization strategy.

Positive

• Commercial stage focusing on expanding fertility treatment accessibility.
• Established operational INVO Centers in North America.
• Flagship product INVOcell offers cost-effective fertility solutions.

Negative

• None.

Financial results to be released after market close;
Conference call to be conducted at 4:30 pm ET

SARASOTA, Fla., April 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell^® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its fourth quarter and fiscal year 2022, for the period ended December 31, 2022, after the market close on Monday, April 17, 2023. The Company has scheduled a conference call that same day, Monday, April 17, 2023, at 4:30 pm ET, to review the results.

Fourth Quarter and Fiscal Year 2022 Conference Call Details

Date and Time: Monday, April 17, 2023 at 4:30 pm ET

Call-in Information: Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ or https://app.webinar.net/2QzngYNWE01.

Replay: A teleconference replay of the call will be available through April 24, 2023, at 877-344-7529 or 412-317-0088, replay access code #1929138. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days. 

About INVO Bioscience

We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell^®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization ("IVF"), the other advanced ART treatment. We believe the IVC procedure can deliver comparable results to IVF and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell^® and IVC procedure (with three centers in North America now operational), and the acquisition of existing IVF clinics, in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-report-fourth-quarter-and-fiscal-year-2022-financial-results-on-monday-april-17-2023-301794917.html

SOURCE INVO Bioscience, Inc.

FAQ

What financial results will INVO Bioscience report?

INVO Bioscience will report its Q4 and fiscal year 2022 financial results on April 17, 2023.

When will the INVO Bioscience conference call take place?

The conference call will be held on April 17, 2023, at 4:30 pm ET.

What is INVOcell?

INVOcell is a medical device that enables intravaginal culture for fertility treatments.

How can I access the INVO Bioscience conference call?

The conference call can be accessed by dialing 833-756-0861 or via live webcast on their Investor Relations website.